Next report date
Report period
Q2 2024
EPS estimate
3.79 KCLP
Revenue estimate
2.27 TCLP
7916.220CLP
1.02 TCLP
8.30 TCLP
144.43 M
About Biogen Inc.
Sector
CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Employees (FY)
7.57 K
Founded
1978
FIGI
BBG00YFSCG08
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BIIBCL is featured.
Frequently Asked Questions
The current price of BIIBCL is 261090.000 CLP — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BCS exchange BIOGEN INC stocks are traded under the ticker BIIBCL.
BIOGEN INC is going to release the next earnings report on Jul 23, 2024. Keep track of upcoming events with our Earnings Calendar.
BIIBCL stock is 35.15% volatile and has beta coefficient of 0.82. Check out the list of the most volatile stocks — is BIOGEN INC there?
BIIBCL earnings for the last quarter are 2.60 K CLP per share, whereas the estimation was 2.81 K CLP resulting in a −7.35% surprise. The estimated earnings for the next quarter are 3.41 K CLP per share. See more details about BIOGEN INC earnings.
BIOGEN INC revenue for the last quarter amounts to 2.10 T CLP despite the estimated figure of 2.17 T CLP. In the next quarter revenue is expected to reach 2.27 T CLP.
Yes, you can track BIOGEN INC financials in yearly and quarterly reports right on TradingView.
BIIBCL net income for the last quarter is 386.82 B CLP, while the quarter before that showed 220.19 B CLP of net income which accounts for 75.67% change. Track more BIOGEN INC financial stats to get the full picture.
Today BIOGEN INC has the market capitalization of 28.97 T, it has decreased by 1.35% over the last week.
No, BIIBCL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BIIBCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGEN INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 7.57 K employees. See our rating of the largest employees — is BIOGEN INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGEN INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGEN INC stock shows the neutral signal. See more of BIOGEN INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on BIOGEN INC future price: according to them, BIIBCL price has a max estimate of 333333.33 CLP and a min estimate of 190476.19 CLP. Read a more detailed BIOGEN INC forecast: see what analysts think of BIOGEN INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGEN INC EBITDA is 2.23 T CLP, and current EBITDA margin is 22.58%. See more stats in BIOGEN INC financial statements.